Resampling‐based stepwise multiple testing procedures with applications to clinical trial data.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 297, doi. 10.1002/pst.2076
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2021 AND VI 20 AND IP 2
Results: 17
1
2
Early stopping in seamless phase I/II clinical trials.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 390, doi. 10.1002/pst.2084
- By:
- Publication type:
- Article
3
Novel concentration‐QTc models for early clinical studies with parallel placebo controls: A simulation study.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 375, doi. 10.1002/pst.2083
- By:
- Publication type:
- Article
4
Joint analysis of longitudinal measurements and survival times with a cure fraction based on partly linear mixed and semiparametric cure models.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 362, doi. 10.1002/pst.2082
- By:
- Publication type:
- Article
5
Dynamic ordering design for dose finding in drug‐combination trials.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 348, doi. 10.1002/pst.2081
- By:
- Publication type:
- Article
6
Assessment of the information theory approach to evaluating time‐to‐event surrogate and true endpoints in a meta‐analytic setting.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 335, doi. 10.1002/pst.2080
- By:
- Publication type:
- Article
7
Estimand framework: Are we asking the right questions? A case study in the solid tumor setting.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 324, doi. 10.1002/pst.2079
- By:
- Publication type:
- Article
8
Defining estimands using a mix of strategies to handle intercurrent events in clinical trials.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 314, doi. 10.1002/pst.2078
- By:
- Publication type:
- Article
9
TSNP: A two‐stage nonparametric phase I/II clinical trial design for immunotherapy.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 282, doi. 10.1002/pst.2075
- By:
- Publication type:
- Article
10
Assessing goodness‐of‐fit for evaluation of dose‐proportionality.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 272, doi. 10.1002/pst.2074
- By:
- Publication type:
- Article
11
Utilizing Bayesian predictive power in clinical trial design.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 256, doi. 10.1002/pst.2073
- By:
- Publication type:
- Article
12
The current state of Bayesian methods in nonclinical pharmaceutical statistics: Survey results and recommendations from the DIA/ASA‐BIOP Nonclinical Bayesian Working Group.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 245, doi. 10.1002/pst.2072
- By:
- Publication type:
- Article
13
The promise and pitfalls of composite endpoints in sepsis and COVID‐19 clinical trials.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 413, doi. 10.1002/pst.2070
- By:
- Publication type:
- Article
14
Sample size calculation for logrank test and prediction of number of events over time.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 229, doi. 10.1002/pst.2069
- By:
- Publication type:
- Article
15
A stochastically curtailed two‐arm randomised phase II trial design for binary outcomes.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 212, doi. 10.1002/pst.2067
- By:
- Publication type:
- Article
16
A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapies.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 202, doi. 10.1002/pst.2066
- By:
- Publication type:
- Article
17
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 199, doi. 10.1002/pst.2034
- Publication type:
- Article